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INTRODUCTION
Contraceptive discontinuation occurs when a woman ceases to use her current method of
contraception. Contraceptive discontinuation is a common occurrence, though rates vary
widely by country. A summary of 18 countries using Demographic and Health Survey
(DHS) data found that between 20% and 50% of users of reversible modern methods of
contraception discontinued their method during the first 12 months of use.1 Similarly, a
more recent study of DHS data from eight countries found the 12 month discontinuation
rates to range between 18 and 49%.2 Contraceptive discontinuation can be “active,” as when
a woman needs to visit a clinic to have her IUD removed, or “passive,” requiring no extra
effort, such as when an appointment for a re-injection is missed or forgotten, or a pill
prescription is not re-filled. Data from a wide range of countries show that contraceptive
methods requiring passive discontinuation, such as oral contraceptive pills, condoms,
injectables such as Depo-Provera, and traditional methods, have higher rates of
discontinuation when compared to methods that require active discontinuation, such as the
IUD and implants.2–6
Contraceptive discontinuation is an important public health concern as it has been shown to
contribute to unplanned pregnancy and unwanted births, which in turn, contribute to
increased maternal, neonatal, and infant morbidity or mortality.7–9 As a consequence,
discontinuation rates can be utilized as a measure of family planning service quality, with
high rates of discontinuation interpreted as a sign of missed opportunities to promote and
sustain contraceptive use.10,11
Notably, not all women who discontinue a contraceptive become nonusers; some women
switch to another more (or less) effective method. The women who continue to want to
avoid a pregnancy and discontinue without switching are at an increased risk of unwanted or
mistimed birth. High quality services, including having a range of methods available and
good counseling on methods, can increase the likelihood that women switch rather than
discontinue all use. Thus, all-method discontinuation, as opposed to method-specific
discontinuation, incorporates switching and more accurately captures the role of
discontinuation for assessing family planning service delivery and quality.12,13 A recent
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examination of oral contraceptive discontinuation and switching behavior in 19 countries
found that, on average, 35% of women discontinuing use of contraception for reasons of
method dissatisfaction switched to another method within three months, leaving the authors
to suggest that more attention should be paid to the issue of method switching as opposed to
simply method discontinuation.3
Whether a woman discontinues a particular contraceptive method and switches to another
method is likely due to a number of factors. For example, women who are no longer in need
of contraception are not likely to switch or re-initiate use. Such women may no longer be
with their partner (due to marital disruption, separation, or death of a spouse), no longer be
able to become pregnant (infecund), or may want to become pregnant. Previous research
estimated that reduced need accounts for 7% to 20% of discontinuation of all reversible
methods.13
Other demographic factors such as age, parity, and union status are most frequently
associated with discontinuation, while education, area of residence and household income
are less consistently so.5,14 However, urban women and women with higher levels of
education and socioeconomic status are more likely to switch methods when they do
discontinue, whereas older age is related to a decreased likelihood of switching.5,6 Side
effects and health concerns are one of the most common reasons women give for
discontinuing a method.1,14 Though the experience of side effects has been shown to
increase the likelihood of method discontinuation,15,16 it is not known if the experience of
side effects is associated with whether or not a woman switches to another method.
Research on service quality and discontinuation has produced mixed results.11, 17–21 Though
few studies have looked specifically at service quality and method switching, a recent study
of switching behaviors in Bangladesh found that women who had more contacts with family
planning outreach workers were less likely to experience discontinuation and nonuse.22
Furthermore, while the characteristics of methods will influence discontinuation, they
should not affect switching behavior as long as other types of contraception are available
and accessible. For example, research from Morocco found that women who lived near
facilities that offered three or more methods were more likely to switch than were women
who lived near facilities that did not offer as many method choices.19
The overall goal of this analysis is to examine the differences between women who reinitiate
contraceptive use immediately after a discontinuation (i.e., switch methods) and women who
discontinue use and do not immediately begin another method (i.e., experience an episode of
nonuse). We assess a number of factors related to contraceptive use and discontinuation, as
identified by previous studies; these include demographic characteristics, fertility desires,
perceived service quality, experience with the method, and experience of side effects while
using the method. We also collected information on women’s contraceptive decision-making
and are thus able to include some variables related to the degree of engagement with partner
and community in discussions of family planning use and decisions to discontinue. We aim
to characterize method switchers in contrast to discontinuers/non-switchers and to use the
comparisons to identify programmatic implications.
The study uses data from Honduras, a small Central American country with a population of
approximately 7.3 million people. Modern contraceptive use is relatively high in Honduras,
with a prevalence of 56.4% among married women ages 15–49 (all information in this
section from Secretaría de Salud [Honduras], 2006).23 Female sterilization is the most
common modern method (21.2%), followed by the reversible methods of interest in this
study; injectables (13.8%) oral contraceptive pills (11.3%) and the IUD (6.6%). The public
sector supplies almost half of the country’s family planning services, with the Secretary of
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Health system of hospitals, CESAMOs (Health Centers with Doctors and Dentists), and
CESARs (Rural Health clinics, staffed by nurses) supplying contraception to 44% of users.
The Honduran Family Planning Association (Asociación Hondureña de Planificación de
Familia or ASHONPLAFA), the local International Planned Parenthood Federation affiliate,
is the country’s main private provider of family planning services, serving 25% of users. Of
note, pharmacies are the most common source of supply for oral contraceptive pills (35.3%).
METHODS
Data
The data for this analysis come from a panel study on the determinants of contraceptive
discontinuation conducted in four urban areas of Honduras: Tegucigalpa, San Pedro Sula,
Santa Rosa de Copán/La Entrada, and Gracias. The data were collected in two rounds, a
baseline interview and a follow-up interview after one year. The baseline data were
collected between October-November 2006 from exit interviews held with eligible women
attending a family planning appointment in selected health facilities in which they received
the injection, oral contraceptive pill, or IUD. Selected clinics for the study included seven
Secretary of Health clinics (CESAMOs), one Secretary of Health hospital, and five
Honduran Family Planning Association (ASHONPLAFA) clinics. Eligible women were
aged 15–44, and were either new or continuing users of one of the three aforementioned
reversible methods. There were no enrollment quotas by type of method. All eligible,
consenting women were interviewed during the observation period until a total of 200
interviews were obtained from each urban area. Overall 800 interviews were completed.
Follow-up data were collected after one year with the same women as interviewed at
baseline. Interviewers used contact information provided by the respondents at baseline to
locate and arrange for the follow-up interviews. Follow-up interviews were conducted in
October-December 2007. A total of 84% of women who participated at baseline (n=671)
were found and interviewed at the one-year follow-up.
The baseline survey questionnaire collected information on demographic characteristics,
birth histories, previous use of contraception, perception of service quality at clinic
appointment, motivation to avoid pregnancies, and the family planning decision-making
environment. The follow-up questionnaire collected information on the use of contraception
during each month since the baseline interview (using a contraceptive calendar), experience
of and reactions to side effects during the follow-up period, and updates on demographics,
fertility motivations, and the decision-making environment.
Some women contributed more than 12 months of contraceptive behavior in the follow-up
period, based on the timing of their interviews. For this analysis, we consider all
discontinuations that occurred in the first 12 months of the study only. There were 16
women who discontinued use of a method in month 12; for all 16 women, we have
information on whether they switched methods or experienced an episode of nonuse. The
analysis sample includes only women who experienced any discontinuation in the follow-up
period (n=273).
Authorization for the study was obtained from the Institutional Review Board (IRB) of the
University of North Carolina at Chapel Hill, the Honduran Secretary of Health, and
ASHONPLAFA. Written consent was obtained from each participant at baseline and follow-
up.
Variables
The data for the dependent variable on discontinuation behavior were extracted from the
contraceptive calendar used to collect month-by-month information on contraceptive use
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during the study period. The dependent variable is constructed from the group of women
who discontinued their baseline method during the first 12 months of the study period
(n=273; 41% of the follow-up sample). Women are considered “switchers” if they began a
method within a month of discontinuing the baseline method. Women are considered
“discontinuers” if they did not use any other method during the follow-up period (including
because of pregnancy) or reinitiated the use of the same or another method after
experiencing at least one month of nonuse. The dependent variable is coded “1” for
switching and “0” for discontinuation with an episode of nonuse.
Independent variables for the analysis include demographic characteristics; fertility desires;
service quality, method characteristics, the experience, perception, and reaction to side
effects; and reason for discontinuation. These variables are listed in Table 1 along with how
they are coded for analysis.
At the baseline exit interview, women were asked a number of questions about the quality of
counseling and service provision during their appointment. Selected indicators of service
quality are shown in Table 1. A number of questions on women’s experiences at the clinic
appointment were not selected for inclusion in the study because they showed little variation
among responses (less than 10% responding in the negative); these included the client’s
level of satisfaction with the cleanliness of the clinic, the level of privacy, the way she was
treated by the provider, and overall satisfaction with care received.
At follow-up women were asked about side effects during the study period, beginning with
whether they experienced any side effects and the number and type of side effects
experienced. The complete list of side effects included abdominal pain, amenorrhea,
dizziness, facial spotting, heavy bleeding, infections, irregular bleeding, nausea/vomiting,
weight gain, and weight loss. The side effects selected for inclusion in the analysis were
mentioned by at least 50 women. It is worth noting that women with no side effects are in
the null category for side effects and communication about side effects variables.
Analysis
A cross-tabulation is constructed to compare a number of characteristics (i.e., the
independent variables) by whether women switched methods or discontinued all methods. A
test of cross-tabulations is then conducted to assess the relationships between the dependent
variable and each independent variable using Pearson’s χ2. The degree of association is
assessed at a 90%, 95%, and 99% level of significance. Independent variables with at least a
90% degree of association with the dependent variable are included for consideration into
the multivariate analysis.
A further descriptive analysis is carried out to investigate attitudes and behaviors of women
discontinuing the baseline method by side effect experienced. The analysis is restricted to
the most common side effects experienced (headaches, amenorrhea, heavy bleeding).
Similar to the cross-tabulation described previously, a test of cross-tabulations is conducted
to assess the relationships between the dependent variable and independent variables of
interest for this sub-sample using Pearson’s χ2. Again, the degree of association is assessed
at a 90%, 95%, and 99% level of significance.
A multivariate logistic regression is conducted to assess differences between women who
switched methods and women who discontinued and experienced an episode of nonuse.
Variables considered for the analysis are those that showed significance in the bivariate
analysis. Associations between predictor variables are examined prior to building the
multivariate model using Spearman’s ρ. Correlation between predictor variables is also
assessed prior to running the regression. In any pair of variables with a correlation greater
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than +/−0.6, a decision was made as to which variable to eliminate from the model. Union
status is captured in the null categories for partner variables. Women not experiencing side
effects are part of null categories. All analyses were run using STATA version 10.1
(STATACorp., College Station, TX, United States).
RESULTS
A total of 273 women (41%) from the full panel sample discontinued using their baseline
method during the first 12 months of the study. Compared to the full panel sample, the 273
women who discontinued were more often not in union at follow-up and were new users of
the method at baseline (results not shown). Table 2 presents characteristics of the full panel
sample by whether women continued using their baseline method throughout the 12 month
study period (n=398) or whether they discontinued use of the baseline method (n=273). A
large difference in these two groups of women was seen in the proportions of women not
currently in union (7.3% of continuers and 15.7% of discontinuers), women who were new
to the method (45.0% and 53.1%, respectively), and women who used the injectable at
baseline (68.8% and 77.7%, respectively). Women who discontinued were also slightly
more likely to be younger, at a lower parity, and from a rural area, as compared to their
counterparts who continued with their baseline method.
Table 3 divides the discontinuers into women who switched to another method (n=117) and
women who discontinued using contraception for one month or more (n=156). As the table
shows, there are only a few variables in which a significant difference is not found. A few
findings are worth noting: women who switched are more likely to be younger and at a
lower parity than women who discontinued. A greater percentage of women who switched
experienced side effects, particularly side effects that interfered with daily activities or
relationships with their partner, than women who discontinued. However, a smaller
percentage of switchers experienced amenorrhea while using their baseline method than the
discontinuers. Another interesting finding is that a significantly greater percentage of
switchers discussed side effects with two or more people, their partner, or a health worker,
than did women who discontinued; this may be a consequence of these women experiencing
more side effects. Women who switched were likely to switch to one of the other methods
included in this analysis: pills accounted for 37% of switches, injectables 21%, and the IUD
14% (results not shown). Also common was switching to traditional methods (14%) and
condoms (13%).
A further descriptive analysis to examine the attitudes and behaviors of women who
discontinued the baseline method and who experienced the same side effect shows that there
are a number of significant differences between women who switched to another method
and women who did not, particularly with regards to health-seeking behavior, discussing
side effects, and in making the decision to stop using the method (Table 4). However, results
should be interpreted with caution due to small sample sizes. Among discontinuers
experiencing amenorrhea (n=66), women who switched methods were significantly more
likely to have sought help from a clinic or health worker and to have discussed side effects
with two or more people than were women with amenorrhea who discontinued use. For
women experiencing heavy bleeding (n=64), switchers were significantly more likely than
discontinuers to have discussed the side effects with two or more people, with their partner
specifically, and to have discussed the decision to stop using their baseline method with their
partner before making the decision to discontinue. Among discontinuers who experienced
headaches (n=82), the only significant difference between switchers and discontinuers was
in the percentage of women who discussed stopping the baseline method with their partner
before making the decision to stop. The results indicated that there were no significant
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differences by perceived severity of the side effect. It is possible that further significant
differences could be detected with larger sample sizes.
A number of variables were not included in the multivariate model due to high correlation
with other variables; these included experience of side effects during the study, discussion of
side effects with two or more people, discussion of side effects with partner, and discussion
of side effects with a health worker. In a multivariate analysis, fewer of the indicator
variables maintain significance with the dependent variable than in the bivariate analysis, as
shown in Table 5. Of demographic variables, only area of residence remains significant, and
indicates that women in urban areas are almost 2.6 times more likely to have switched
methods than to discontinue all methods. New and recent adopters are, respectively, 2.3 and
3.5 times more likely to have switched methods than discontinue all use as compared to
women who were using for a longer period. As in the bivariate comparison, experiencing
amenorrhea was associated with a reduced likelihood of switching methods. However, while
heavy bleeding was significantly related to switching in the bivariate analysis, in the
multivariate context, the reverse was true (with a p-value of 0.076). In particular, women
who experienced heavy bleeding were somewhat more likely to discontinue than switch as
compared to women who did not experience heavy bleeding. The effect of side effects and
related behaviors may be affected by the inclusion of women with no side effects in the null
categories of these variables. Women who sought help with side effects from a clinic or
health worker and women who discussed stopping the method with their partner before
making a decision to stop were also significantly more likely to have switched to another
method.
CONCLUSION
Contraceptive discontinuation was high for women in the study population, as more than
four out of 10 women discontinued the use of their baseline method within the 12-month
study period. Nearly 43% of these women then switched to another method without
experiencing an episode (one month) of nonuse. The analysis found that there were
significant differences by demographics, the experience of side effects, discussing the
decision to discontinue, and in the main reasons for discontinuation between switchers and
discontinuers.
There were some limitations to the analysis. One limitation is that there is right and left
censoring of the data for the periods before and after the study period. The focus of the
analysis is on the discontinuation event and what happened in the next month, as a result
there is also censoring of the data due to analytical constraints. For example, women who
were categorized as “switchers” may not have continued using the new method for longer
than a single month, or the index month following discontinuation of the baseline method.
Likewise, women labeled as “discontinuers” may have reinitiated or switched methods after
a lapse of one month or more, in effect becoming “switchers.” Some of these issues could be
addressed with a larger study population and longer period of observation.
In the literature, successful switching is also assessed for the first three months after the
discontinuation event, even though pregnancies can occur during this period (for example,
as assessed in Ali and Cleland).3 However, the use of a one-month episode may not
significantly affect results: Research from the 2002 U.S. National Survey of Family Growth
found that most switching occurs in the first month after discontinuation; the probability of
resuming use of contraception after discontinuation was 72% in the first month, only
increasing to 76% by three months.24
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Another limitation is that switching behavior, rather than duration of contraceptive use was
assessed in this analysis. It is possible that a woman who discontinued the baseline method
early in the study period and then switched to another method may have subsequently
discontinued; this woman may have had fewer months of contraceptive use than another
woman who discontinued and did not adopt another method at month 11. With the data
available from only a one-year period, it is not possible to examine this level of depth of use,
though we do know that the mean time until discontinuation of the baseline method was
very similar for both groups of women: 6.0 months for switchers and 6.4 months for
discontinuers.
Despite these limitations, a number of interesting findings emerged from the study.
Multivariate analysis found that women living in urban areas were more likely to have been
“switchers” than “discontinuers.” There are a number of potential factors contributing to this
finding, including the fact that more women from urban areas were using IUDs, which
require a decision to discontinue and an opportunistic visit to a clinic; as well as the fact that
women from urban areas were likely to benefit from easier access to family planning
services, including a better supply and broader variety of providers, and perhaps even higher
diversity in available methods. Limited access to services may also be prohibitive to method
switching if women are not encouraged to seek help from a clinic or health worker when
experiencing side effects.
In fact, of all variables related to side effects, treatment seeking behavior (sought help from
a health clinic) was found to be most significantly related to method switching. Though side
effects may be responsible for contributing to method discontinuation, their relationship
with subsequent method use is less clear. Our findings suggest that only the experience of
amenorrhea has a negative impact on switching behavior. This too suggests an active
approach to discontinuation, though with the reverse effect, as it is often in response to the
amenorrhea that new methods are not immediately initiated. Formative qualitative work in
Honduras with current and previous users of contraception indicates that women discontinue
when experiencing amenorrhea for two main reasons: to determine their pregnancy status
and to re-establish what are considered “healthy” menstrual patterns. In the current study,
amenorrhea was most commonly experienced by users of the injectable. Such findings
highlight an opportunity for providers to counsel and educate about amenorrhea during the
initiation of the injectable and to discuss the adoption of non-hormonal barrier methods with
women who otherwise may “take a break” from contraception because they want to
determine whether or not they are pregnant.
Finally, another of the interesting findings from the study is in the significant influence of
discussing the option to discontinue with the partner, before making the decision to
discontinue the method. The study did not, however, determine what it is about discussions
with the partner (and others) that are supportive of switching behavior. Do discussions
represent a reinforcement of the decision to use family planning and encouragement to try a
different method (i.e., is it the quality of the discussion)? Or does the indicator represent the
value of being in supportive relationships, and being able to confide troubles and discuss
family planning options with a partner/spouse or others (i.e., is it the quality of the
relationship)? Definitive answers to these questions are beyond the scope of the present
research, yet offer interesting avenues for further investigation. Based on our findings,
however, we propose that the discussions lead to a greater likelihood of switching and thus
should be encouraged and supported by Honduran family planning programs seeking to
improve the likelihood of contraceptive continuation.
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Table 1
Definition of predictor variables
Variable Coding for analysis
Demographic characteristics
  Age 15–24; 25–34; 35–44
  Education None; Primary; Secondary or higher
  Parity Univariate and bivariate: 0–1; 2–3; 4+
Multivariate: 0–1, 2+
  Union statusa Married or in union; Not in union
  Residencea Rural; Urban
  Monthly household income Lower if < 3000 Lempiras (USD$158);
Middle if between 3000–5000 Lempiras (USD$158–264)
Higher if > 5000 Lempiras (USD$264)
Fertility desires Desires another child within 2 years, “soon” or “now”
Desires another child after two years or don’t know when
Desires no more children or is undecided
Service quality
    Had all questions answered by provider Yes; No
    Received info. on how to use method effectively Yes; No
    Received info. on advantages/disadvantages of method Yes; No
    Ever informed about side effects of their method Yes; No
Method characteristics
    Length of use at baseline Used method >1 year; Used method ≤1 year; New to method on day of
appointment
    Method used at baseline IUD; Injectable; Pill
Experience with side effects
    Had side effects during study period Yes; No
    Had 2 or more side effects during study period Yes; No
    Type of side effect experienced
      Abdominal pain Yes; No or no side effect
      Amenorrhea Yes; No or no side effect
      Dizziness Yes; No or no side effect
      Headaches Yes; No or no side effect
      Heavy bleeding Yes; No or no side effect
      Weight gain Yes; No or no side effect
    Felt side effects interfered with daily activities Yes; No or no side effect
    Felt side effects interfered with relationship with partner Yes; No or no side effect
    Self-medicated or took home remedies Yes; No or no side effect
    Sought help from a clinic or health worker Yes; No or no side effect
Communication with others
  Discussed side effects with 2 or more people Yes; No or no side effect
  Discussed side effects with partner Yes; No or no side effect
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Variable Coding for analysis
  Discussed side effects with family member(s) Yes; No or no side effect
  Discussed side effects with friends Yes; No or no side effect
  Discussed side effects with health worker Yes; No or no side effect
  Discussed stopping BL method with partner before making
decision to discontinue
Yes; No
Main reason for discontinuation Reduced Need (want to become pregnant, infrequent sex, partner not
present, marital dissolution or separation)
Problems with method (became pregnant while using, side effects, health
concerns, method difficult to use, want a more effective method)
Other (partner does not approve, access issues, missed appointments,
method not available, “other”)
a
Assessed at follow-up; otherwise all demographic, fertility desires, service quality, and method characteristics variables measured assessed at
baseline
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  15–24 45.5 49.5
  25–34 46.0 43.2
  35–44 8.5 7.3
Education
  None 6.0 5.5
  Primary 65.1 63.7
  Secondary or higher 28.9 30.8
Parity
  0–1 41.7 47.6
  2–3 42.7 41.4
  4+ 15.6 11.0
Union statusa,***
  Married or in union 92.7 84.3
  Not in union 7.3 15.7
Residencea
  Rural 20.8 25.3
  Urban 79.2 74.7
Monthly household income
  Lower 47.5 50.9
  Middle 30.4 27.1
  Higher
Length of use at baseline*
  Used method >1 year 34.1 27.5
  Used method ≤1 year 20.9 19.4
  New to method 45.0 53.1
Method used at baseline**
  IUD 25.4 14.3
  Injectable 68.8 77.7
  Pill 5.8 8.1
a
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Table 3
Women’s contraceptive use status after discontinuation of baseline method, by selected characteristics,
Honduras, 2006–2007; N=273








    15–24 58.1 43.0
    25–34 37.6 47.4
    35–44 4.3 9.6
  Education**
    None 3.4 7.0
    Primary 57.3 68.6
    Secondary+ 39.3 24.4
  Parity**
      0–1 54.7 42.3
      2+ 45.3 57.7
  Union Status**
    In union 89.7 80.1
    Not in union 10.3 19.9
  Residence***
    Rural 16.2 32.0
    Urban 83.8 68.0
  Monthly household income
      Lower 45.3 55.1
      Middle 29.9 25.0
      Higher 24.8 19.9
Fertility desires
  Fertility desires***
    Desire another child < 2 years 6.8 19.2
    Desire another child > 2 years or DK when 55.6 39.1
    Desires no more children 28.2 35.9
    Undecided 9.4 5.6
Service quality
  Had all questions answered by provider*** 72.7 50.0
  Received info. on how to use method effectively 52.1 43.6
  Received info. on advantages/disadvantages of method* 44.4 34.6
  Ever informed about side effects of their method 69.2 65.4
Method characteristics
  Length of use at baseline***
    Used method >1 year 15.4 36.5
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    Used method ≤1 year 23.1 16.7
    New to method 61.5 46.8
  Method used at baseline**
    IUD 20.5 9.6
    Injectable 73.5 80.8
    Pills 6.0 9.6
Experience with side effects
  Had side effects during study period*** 89.7 69.9
  Had 2 or more side effects during study period*** 60.7 41.7
  Type of side effect experienced
    Abdominal pain*** 23.9 11.5
    Amenorrhea* 18.8 28.2
    Dizziness 18.8 18.6
    Headaches 30.8 29.5
    Heavy bleeding** 30.8 18.0
    Weight gain 20.5 14.1
  Felt side effects interfered with daily activities*** 54.7 35.3
  Felt side effects interfered with relationship with partner*** 41.0 23.7
  Self-medicated or took home remedies 23.1 20.5
  Sought help from a clinic or health worker*** 55.6 28.2
Communication with others
  Discussed side effects with 2 or more people*** 57.3 32.1
  Discussed side effects with partner*** 63.3 37.2
  Discussed side effects with family member(s) 35.0 26.3
  Discussed side effects with friends* 18.0 10.9
  Discussed side effects with health worker*** 48.8 26.9
  Discussed stopping BL method with partner before making decision to discontinue*** 86.3 60.3
Main reason for discontinuation of BL method*** (n=114) (n=156)
  Reduced need 3.5 44.9
  Problems with method 87.7 48.7
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Table 4
Women’s contraceptive use status after discontinuation of baseline method among women experiencing the
same side effect, by selected characteristics, Honduras, 2006–2007






  Side effects interfered with daily activities 59.1 43.2
  Side effects interfered with relationship with partner 27.3 20.5
  Self-medicated or took home remedies* 13.6 34.1
  Sought help from a clinic or health worker** 63.6 36.4
  Discussed side effects with 2 or more people* 95.5 79.6
  Discussed side effects with partner 68.2 50.0
  Discussed side effects with family member(s) 40.9 31.8
  Discussed side effects with friends 9.1 9.1
  Discussed stopping baseline method with partner before making decision to discontinue 90.9 77.3
Discontinuation with heavy bleeding (N=64) Switched n=36 % Discontinued N=28 %
  Side effects interfered with daily activities 75.0 75.0
  Side effects interfered with relationship with partner 72.2 71.4
  Self-medicated or took home remedies 19.4 21.4
  Sought help from a clinic or health worker 72.2 57.1
  Discussed side effects with 2 or more people** 100.0 85.7
  Discussed side effects with partner*** 80.6 46.4
  Discussed side effects with family member(s) 38.9 42.9
  Discussed side effects with friends 19.4 25.0
  Discussed stopping baseline method with partner before making decision to discontinue*** 97.2 67.9
Discontinuation with headaches (N=82) Switched n=36 % Discontinued N=46 %
  Side effects interfered with daily activities 66.7 71.7
  Side effects interfered with relationship with partner 41.7 47.8
  Self-medicated or took home remedies* 36.1 56.5
  Sought help from a clinic or health worker 58.3 45.7
  Discussed side effects with 2 or more people 94.4 89.1
  Discussed side effects with partner 69.4 63.0
  Discussed side effects with family member(s) 33.3 43.5
  Discussed side effects with friends 19.4 15.2
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Table 5
Odds ratios (OR) from multivariate logistic regression of method switching versus discontinuation of use, by
selected characteristics, Honduras, 2006–2007; N=270a
Independent variables OR C.I.
Demographic characteristics
  Age
    15–24 REF
    25–34 0.75 0.34–1.65
    35–44 0.86 0.20–3.81
  Education
    None REF
    Primary 1.11 0.24–5.10
    Secondary+ 1.91 0.38–9.66
  Parity
      0–1 REF
      2+ 0.96 0.43–2.14
  Residence
    Rural REF
    Urban 2.58 1.17–5.68 **
Fertility desires
  Desire another child < 2 years/undecided REF
  Desire another child > 2 years/don’t know when 1.60 0.68–3.76
  Desire no more children 1.20 0.45–3.20
Service quality
  Had all questions answered by provider 1.63 0.79–3.36
  Received info. on advantages/disadvantages of method 0.88 0.43–1.78
Method characteristics
  Length of use at baseline
    Used method>1 year REF
    Used method ≤1 year 3.45 1.30–9.16 **
    New to method 2.26 097–5.25 *
  Method used at baseline
      IUD REF
      Injectables 0.84 0.29–2.46
      Pill 0.60 0.14–2.66
Experience with side effects
  Had 2 or more side effects during study period 1.26 0.58–2.73
  Type of side effect experienced
      Abdominal pain 1.54 0.56–4.19
      Heavy bleeding 0.44 0.18–1.09 *
      Amenorrhea 0.34 0.14–0.81 **
  Side effects interfered with daily activities 1.22 0.53–2.81
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Independent variables OR C.I.
  Side effects interfered with relationship with husband 0.96 0.41–2.24
  Sought help from a clinic or health worker 2.01 1.01–3.99 **
Communication with others
    Discussed side effects with friends 1.05 0.44–2.49
    Discussed stopping method with partner before making decision to discontinue 3.16 1.43–6.96 **
Main reason for discontinuation
    Reduced need/other REF











Int Perspect Sex Reprod Health. Author manuscript; available in PMC 2014 January 22.
